Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16312989 | 0.86 | NR3C1 (0.46) | NR3C1PGR | |
| SCHEMBL1141818 | 0.83 | NR3C1 (0.49) | NR3C1PGR | |
| SCHEMBL1141814 | 0.83 | NR3C1 (0.49) | NR3C1PGR | |
| SCHEMBL1141548 | 0.82 | NR3C1 (0.48) | NR3C1PGR | |
| SCHEMBL1141824 | 0.79 | NR3C1 (0.54) | NR3C1PGR | |
| SCHEMBL1142496 | 0.79 | NR3C1 (0.54) | NR3C1PGR | |
| SCHEMBL1141833 | 0.77 | NR3C1 (0.55) | NR3C1PGR | |
| SCHEMBL1142066 | 0.77 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL1142069 | 0.77 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL1142617 | 0.77 | NR3C1 (0.52) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896424-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | claimed |
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-07 | — | — | US | claimed |
| EP-1896424-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7888381-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | NR0B1, NR3C1, NFKB2 | NR3C1 2/4885PGR 1018/4885GAA 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.